论文部分内容阅读
自六十年代后期以来,患血友病A的病人用血浆浓缩物进行治疗,在以后的二十年中,以冷沉淀为原料提制的几种中间体以及高度纯化制品的各种类型浓缩物已被使用。最近,应用免疫吸附剂获得的高纯因子Ⅷ浓缩物已制备出来 表1概括了因子Ⅷ浓缩物在质量上的进展。为急需提高浓缩物的质量,则要求减少异源蛋白质的含量,依据一些体外研究报道此异源蛋白质可引起免疫抑制。此外,自1984年以来尽管所有的血浆衍生物均经过了病毒灭活过程。这些高纯浓缩物也还要求尽可能减少病毒污染。
Since the late 1960s, patients with hemophilia A have been treated with plasma concentrates. During the next two decades, several intermediates prepared from cryoprecipitate and various types of concentrated products of highly purified preparations Things have been used. Recently, high purity factor VIII concentrates obtained using immunosorbents have been prepared. Table 1 summarizes the qualitative progression of factor VIII concentrates. In urgent need of improving the quality of the concentrate, it is required to reduce the content of the heterologous protein, which according to some in vitro studies reports that this heterologous protein can cause immunosuppression. In addition, although all plasma derivatives have undergone virus inactivation since 1984. These high purity concentrates also require minimization of virus contamination.